Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate ... representative in the GLP-1 agonist market to testify at the hearing. At BIO 2025, vaccines were ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk A/S (NYSE: NVO), Lars Fruergaard Jørgensen is on the outs. On May 16, Novo made the announcement ...

The sudden departure of Novo Nordisk chief executive Lars Fruergaard Jørgensen comes not amid scandal or strategic calamity, but a less fashionable misstep: disappointing the stock market.

President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. Where to invest $1,000 right now? Our analyst team just ...

the former Novo Nordisk CEO and now chair of the Foundation, will have to find a replacement who can spearhead a battle against Lilly and other rivals, while not abandoning the company’s prized ...